



Processing data for your practice



Present

YEAR IN REVIEW
**BREAST
CANCER**
The year that was...2018

SAT 19th - SUN 20th JAN, 2019. ITC GRAND CENTRAL, PAREL, MUMBAI

Dear Colleagues,

Women's Cancer Initiative - Tata Memorial Hospital and Nag Foundation are delighted to invite you for the "4th Edition of Year In Review: Breast Cancer Conference". This conference will be held on Sat 19th - Sun 20th Jan 2019, at Hotel ITC Grand Central, Parel, Mumbai.

Our idea is to recapitulate the best breast cancer science every year in a "Year in Review" format. The theme of this meeting is "Breast Cancer... the year that was 2018". We strive to recapitulate the best original science presented at the major international conferences of the immediately preceding year and important journals.

From these major conferences and publications, we intend to cover surgical, radiation, medical, pathology, biomarkers and imaging issues making this meeting a truly multi- disciplinary one.

We believe that presentation of the most impactful and important abstracts/full text publications will give the participants a feel of the landscape of breast cancer research, especially that impacts practice. Keynote talks, debate and rapid reviews are also important highlight of this conference. The selection of abstracts/full text publications is based on originality, innovations and potential impact on clinical practice.

The meeting proceedings of the 1st, 2nd and 3rd Year In Review Conferences and many more meetings are fully archived on www.yearinreview.in

We hope to benefit from your presence and wisdom in initiating, undertaking and nurturing this idea.

Regards,

Conference Chairpersons
Dr. Sudeep Gupta
Dr. Shona Nag

International Faculty

Dr. Hope Rugo, USA
Dr. Shaheenah Dawood, Dubai
Dr. Shanu Modi, USA

Scientific Committee

Dr. Amit Agarwal
Dr. Amit Verma
Dr. Anusheel Munshi
Dr. Bhawna Sirohi
Dr. Chirag Desai
Dr. Govind Babu
Dr. G. S. Bhattacharyya
Dr. Hemant Malhotra
Dr. Hope Rugo
Dr. Nishitha Shetty
Dr. Nita Nair
Dr. Shaheenah Dawood
Dr. Shalaka Joshi
Dr. Sanjoy Chatterjee
Dr. Senthil Rajappa
Dr. Randeep Singh
Dr. T. Raja
Dr. Vineet Gupta

2018 Conferences Reviewed

AACR Annual Meeting

(American Association for Cancer Research)

ASCO Annual Meeting

(American Society of Clinical Oncology)

ESMO Annual Meeting

(European Society for Medical Oncology)

SABCS Annual Meeting

(San Antonio Breast Cancer Symposium)

ASTRO Annual Meeting

(American Society for Radiation Oncology)

ESTRO Annual Meeting

(European Society for Radiotherapy and Oncology)

St. Gallen Breast Cancer Conference

ESO-ESMO ABC4 Annual Meeting

(ESO-ESMO Advanced Breast Cancer)

COBRCA Annual Meeting

(Controversies In Breast Cancer)

Milan Breast Cancer Conference

ABS Annual Meeting

(Association of Breast Surgery)

ASBS Annual Meeting

(American Society of Breast Surgeons)

Journals Reviewed

- New England of Journal of Medicine
- Journal of Clinical Oncology
- Annals of Oncology
- Annals of Surgery
- Journal of National Cancer Institute
- JAMA Oncology
- The Lancet
- Lancet Oncology
- Nature
- Nature Genetics
- British Journal of Cancer
- European Journal of Cancer
- The Oncologist
- International Journal of Radiation Oncology, Biology & Physics
- Clinical Cancer Research
- Journal of Experimental & Clinical Cancer Research
- JAMA Cardiology
- PLOS Genetics
- Breast Cancer Research
- Bio Medical Central

-And many more

Websites Reviewed

- Practice Update
- ASCOPOST
- ASCO Reading Room
- Clinical Cancer Options
- Prime Oncology
- Medscape
- Oncolive

-And many more

Session Classifications

- Loco-regional
- HER2 positive
- Supportive Care
- ER positive
- Translational Science
- Triple Negative
- Rapid Reviews
- Debate
- Keynotes



Highlights of the Meeting

02

Major International
conferences
journals & websites
reviewed

03

Keynote talks
& Debate

04

More than 100
abstracts to
be discussed

01

Comprehensive
update on
breast cancer


05

Practice
impacting panel
discussions





About International Faculty



Dr. Hope Rugo, USA

Clinical Professor, Department of Medicine (Hematology/Oncology);
and Director, Breast Oncology Clinical Trials Program, UCSF
San Francisco, CA

Dr. Hope Rugo is a medical oncologist and hematologist specializing in breast cancer research and treatment. A Clinical Professor of Medicine, Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at UCSF in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer. She entered the field of breast cancer in order to incorporate novel therapies based on an understanding of the biology of cancer with excellent quality of care into the treatment of women with breast cancer.

Dr. Rugo is the Director of the Breast Oncology Clinical Trials Program, and is the principal investigator of multiple clinical trials focusing on combining novel targeted therapeutics with standard treatment to improve the treatment of both early and late stage breast cancer. In addition, Dr. Rugo is working on studies to evaluate cognitive function in women receiving chemotherapy for breast cancer, as well as novel ways to reduce toxicity from therapy. Dr. Rugo has established collaborations with a number of other large academic medical centers for the purpose of expanding the novel therapies that are available for our patients, including herbal agents that appear to have an antitumor effect in the laboratory. She is an active member of the national cooperative group, CALGB, and she is a founding member of the Breast Cancer Research Consortium, as well as serving as an investigator in the UCSF Breast SPORC (the Bay Area Specialized Program of Research Excellence in Breast Cancer). Dr. Rugo teaches medical students, physicians and regularly lectures locally, nationally and internationally on subjects relating to the treatment of breast cancer. At UCSF, Dr. Rugo runs the Breast Forum, an open bimonthly evening educational session for breast cancer patients, families and friends from throughout the bay area.

Dr. Rugo graduated from the University of Pennsylvania School of Medicine in 1983. She completed a residency in internal medicine and primary care followed by a fellowship in hematology and oncology at the University of California San Francisco. She was a post-doctoral fellow in immunology participating in laboratory research at Stanford University from 1988-1990. In 1990, Dr. Rugo joined the faculty at UCSF in the Division of Hematology and Oncology. Dr. Rugo has been recognized for her excellence in both patient care and in teaching of both medical students and training physicians. She has received several awards including the Bank of America Gianini Foundation Award and a UCSF Clinical Cancer Center Investigator Research Program intra-mural award. In 2006, she was honored for her work in Breast Cancer Research by the Friends of the Breast Care Center.

About International Faculty



Dr. Shaheenah Dawood, Dubai
M. B. B.Ch

Dr. Shaheenah Dawood is the Head of Medical Oncology and the Head of the Breast Cancer Program at Dubai Hospital in the United Arab Emirates. Dr. Dawood completed her M.B.B.Ch at Dubai Medical College in 1998 and a Master of Public Health degree at the Harvard School of Public Health, Boston, USA in 2008. Her postgraduate medical training programs include a Fellowship at McGill University in Canada in 2006, and the Susan Komen Breast Cancer Fellowship at the University of Texas M.D. Anderson Cancer Center in 2007.

Dr. Dawood is a member of various professional organizations, including the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR), the Canadian Association of Medical Oncologists, the Emirates Medical Association, and the Inflammatory Breast Cancer Research Group. She is also the co-director of the Middle East Research Network.

Dr. Dawood has been a primary author or collaborator on over 50 peer-reviewed publications in national and international journals. In addition, she has collaborated with other authors to write a number of book chapters. Dr. Dawood has also been involved as a journal reviewer and as an editorial consultant for many cancer-related journals.

Research Interests:

Dr. Dawood's researcher interests encompass Triple Negative Breast Cancer, Inflammatory Breast Cancer, Metastases, as well as life-style issues and survival outcome of cancer patients.



Dr. Shanu Modi, USA

Dr. Modi graduated from University of Alberta Faculty of Medicine & Dentistry in 1995 and has been in practice for 14 years. She completed a residency at Memorial Sloan Kettering Cancer Center. Dr. Modi also specializes in Internal Medicine. She currently practices at Memorial Sloan Kettering and is affiliated with Memorial Sloan-Kettering Cancer Center. Dr. Modi accepts multiple insurance plans including Aetna, MVP Health Plan and Medicare. Dr. Modi also practices at Memorial Sloan Kettering Cancer Center in New York, NY.



National Faculty

Dr. A. K. Malhotra, Kolkata	Dr. Ghanshyam Biswas, Bhubaneshwar	Dr. Randeep Singh, Delhi
Dr. Adwaita Gore, Mumbai	Dr. Govind Babu, Bangalore	Dr. Rejiv Rajendranath, Chennai
Dr. Amish Dalal, Mumbai	Dr. Gurpreet Singh, Chandigarh	Dr. Roshni Pande, Jabalpur
Dr. Amish Vora, Delhi	Dr. Harit Chaturvedi, Delhi	Dr. S. H. Advani, Mumbai
Dr. Amit Agarwal, Delhi	Dr. Hemant Malhotra, Jaipur	Dr. Sachin Hingmire, Pune
Dr. Amit Rauthan, Bangalore	Dr. Indoo Ambulkar, Mumbai	Dr. Sandeep Goyle, Mumbai
Dr. Amit Verma, Delhi	Dr. Jatin Sarin, Chandigarh	Dr. Sanjay Deshmukh, Pune
Dr. Amol Dongre, Nagpur	Dr. Jaya Ghosh, Mumbai	Dr. Sanjay M. H., Pune
Dr. Anand Pathak, Nagpur	Dr. Jyoti Bajpai, Mumbai	Dr. Sanjit Agrawal, Kolkata
Dr. Anil Heroor, Mumbai	Dr. K. Geeta, Delhi	Dr. Sanjoy Chatterjee, Kolkata
Dr. Anita Ramesh, Chennai	Dr. K. Pavithran, Cochin	Dr. Saurabh Kumar, Ranchi
Dr. Anubha Bharthuar, Jalandhar	Dr. K. Sambasivaiah, Hyderabad	Dr. Seema Gulia, Mumbai
Dr. Anupama Mane, Pune	Dr. M Vamshi Krishna, Hyderabad	Dr. Selvi Radhakrishna, Chennai
Dr. Anusheel Munshi, Delhi	Dr. M. V. Chandrakanth, Kolkata	Dr. Senthil Rajappa, Hyderabad
Dr. Arun Kumar Goel, Delhi	Dr. Madhuchanda Kar, Kolkata	Dr. Sewanti Limaye, Mumbai
Dr. Arun Warriar, Cochin	Dr. Mandar Nadkarni, Mumbai	Dr. Shailesh Bondarde, Nashik
Dr. Arvind Krishnamurthy, Chennai	Dr. Manish Singhal, Delhi	Dr. Shalaka Joshi, Mumbai
Dr. Asha Kapadia, Mumbai	Dr. Mansi Sharma, Delhi	Dr. Shekhar Patil, Bangalore
Dr. Ashish Bakshi, Mumbai	Dr. Monica Malik, Hyderabad	Dr. Shirish Alurkar, Ahmedabad
Dr. Ashish Kaushal, Ahmedabad	Dr. Muzammil Shaikh, Mumbai	Dr. Shishir Shetty, Mumbai
Dr. Ashish Singh, Vellore	Dr. N. K. Warriar, Calicut	Dr. Shona Nag, Pune
Dr. Atul Batra, Delhi	Dr. Namita Pandey, Mumbai	Dr. Shyam Aggarwal, Delhi
Dr. Atul Sharma, Delhi	Dr. Nikhil Ghadyalpatil, Hyderabad	Dr. Sidharth Sahni, Delhi
Dr. Avinash Deo, Mumbai	Dr. Nita Nair, Mumbai	Dr. Suchanda Goswami, Kolkata
Dr. B. K. Smruti, Mumbai	Dr. Nitesh Rohatgi, Delhi	Dr. Sudeep Gupta, Mumbai
Dr. Bharat Bhosale, Mumbai	Dr. P. P. Bapsy, Bangalore	Dr. Sushil Mandhania, Nagpur
Dr. Bharat Parikh, Ahmedabad	Dr. Peush Bajpai, Delhi	Dr. Sushmita Rath, Mumbai
Dr. Bharath Rangarajan, Coimbatore	Dr. Poonam Patil, Bangalore	Dr. T. P. Sahoo, Bhopal
Dr. Bhawna Sirohi, Delhi	Dr. Prasad Narayanan, Bangalore	Dr. Tabassum W., Mumbai
Dr. BKC Mohan Prasad, Madurai	Dr. Prasanth Ganesan, Chennai	Dr. Tanuja Shet, Mumbai
Dr. Boman Dhabhar, Mumbai	Dr. Prasenjit Chatterjee, Kolkata	Dr. Tanveer Maksud, Surat
Dr. C. J. Tamane, Aurangabad	Dr. Priya Tiwari, Delhi	Dr. Tanveer Shahid, Kolkata
Dr. Chetan Deshmukh, Pune	Dr. R. A. Badwe, Mumbai	Dr. Tapan Saikia, Mumbai
Dr. Chirag Desai, Ahmedabad	Dr. R. Gopal, Mumbai	Dr. Tejinder Singh, Mumbai
Dr. D. C. Doval, Delhi	Dr. R. K. Deshpande, Mumbai	Dr. U. Suryanarayana, Ahmedabad
Dr. D. K. Vijaykumar, Cochin	Dr. Raghunadharao Digumarti, Hyderabad	Dr. V. Lokesh, Bangalore
Dr. Dharmesh Soneji, Delhi	Dr. Rahul Kulkarni, Pune	Dr. Vedant Kabra, Delhi
Dr. G. S. Bhattacharyya, Kolkata	Dr. Raj Nagarkar, Nashik	Dr. Vibhor Sharma, Delhi
Dr. G. S. Chowdhary, Mumbai	Dr. Rajiv Sarin, Mumbai	Dr. Vikram Maiya, Bangalore
Dr. G. Suryanarayana Raju, Hyderabad	Dr. Rakesh Taran, Indore	Dr. Vinayak Maka, Bangalore
Dr. Garvit Chitkara, Mumbai	Dr. Ramesh Nimmagadda, Chennai	Dr. Virendra Vyas, Wardha
Dr. Gaurav Gupta, Lucknow	Dr. Ramesh Sarin, Delhi	



Scientific Program

Day 1, Saturday 19th January 2019

08:00 - 09:00

Registration

09:00 - 11:10 **SESSION 1 : LOCO-REGIONAL**

09:00 - 09:30

Keynote 1: Evolution of Breast Cancer Care: A Surgeon's Perspective

Speaker: Dr. R. A. Badwe

09:30 - 09:40

Abstract 1: Three-Year Outcomes With Hypofractionated Versus Conventionally Fractionated Whole-Breast Irradiation: Results of a Randomized, Noninferiority Clinical Trial

Author: Simona F. Shaitelman, et al.

Citation: J Clin Oncol. 2018 Oct 31;JCO1800317. [Epub ahead of print]

Abstract 2: Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer

Author: Vicini FA

Citation: SABCS 2018, GS4-04

09:40 - 09:50

Abstract 3 : Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: 10 year follow up results of the EORTC AMAROS trial (EORTC 10981/22023)

Author: Rutgers EJ

Citation: SABCS 2018, GS4-01

Abstract 4 : Chest Wall Resection for Recurrent Breast Cancer in the Modern Era: A Systematic Review and Meta-analysis

Author: Elliot Wakeam

Citation: Ann Surg. 2018 Apr;267(4):646-655

09:50 - 10:00


Abstract 5: Local therapy and quality of life outcomes in young women with breast cancer

Author: Dominici LS

Citation: SABCS 2018, GS6-06



Day 1, Saturday 19th January 2019


-  Abstract 6: Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial

Author: Viviana Galimberti, et al.

Citation: Lancet Oncol. 2018 Oct;19(10):1385-1393


10:00 - 10:15

Rapid Review 1: Loco-regional

-  Abstract 1 : The impact of breast cancer surgery on quality of life: Long term results from E5103


Author: Rosenberg SM

Citation: SABCS 2018, GS6-05

-  Abstract 2 : Does resection of cavity shave margins result in lower positive margin and re-excision rates in patients with stage 0-III breast cancer? Results from a prospective multicenter randomized controlled trial


Author: Chagpar AB

Citation: SABCS 2018, PD8-07

-  Abstract 3: US FDA Breast Implant Postapproval Studies Long-term Outcomes in 99,993 Patients


Author: Coroneos CJ, et al.

Citation: Ann Surg. 2019 Jan;269(1):30-36

-  Abstract 4 : Long-term Follow-up of Autologous Fat Transfer vs Conventional Breast Reconstruction and Association With Cancer Relapse in Patients With Breast Cancer


Author: Krastev T

Citation: JAMA Surg. 2018 Oct 10. [Epub ahead of print]

-  Abstract 5: Prophylactic Irradiation to the Contralateral Breast for BRCA Mutation Carriers with Early Stage Breast Cancer




Author: E. Evron, et al.

Citation: Ann Oncol. 2018 Nov 23. [Epub ahead of print]

-  Abstract 6: Association of Circulating Tumor Cell Status With Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer





Author: Chelain R. Goodman, et al.

Citation: JAMA Oncol. 2018 Aug 1;4(8):e180163. [Epub 2018 Aug 9]

-  Abstract 7: Comparison of 2-Year Complication Rates Among Common Techniques for Postmastectomy Breast Reconstruction
Author: Katelyn G. Bennett, et al.
Citation: JAMA Surg. 2018 Oct 1;153(10):901-908
-  Abstract 8: Risk of Synchronous Distant Recurrence at Time of Locoregional Recurrence in Patients With Stage II and III Breast Cancer (AFT-01)
Author: Heather B. Neuman, et al.
Citation: J Clin Oncol. 2018 Apr 1;36(10):975-980
-  Abstract 9: Quality of life and patient satisfaction after one-stage implant-based breast reconstruction with an acellular dermal matrix versus two-stage breast reconstruction (BRIOS): primary outcome of a randomised, controlled trial
Author: Vera Lidwina Negenborn, et al.
Citation: Lancet Oncol. 2018 Sep;19(9):1205-1214




10:15 - 10:30

Rapid Review 2: Loco-regional

-  Abstract 1: Prophylactic Irradiation to the Contralateral Breast for BRCA Mutation Carriers with Early Stage Breast Cancer
Author: Evron E
Citation: Ann Oncol. 2018 Nov 23. [Epub ahead of print]
-  Abstract 2: Multicenter study to standardize and evaluate the efficacy of radiofrequency ablation therapy for early breast cancer (RAFAELO study)
Author: Kinosita T.
Citation: SABCS 2018, OT2-03-01
-  Abstract 3: Phase II trial of pre-operative stereotactic ablative radiotherapy (SABR) in early-stage breast cancer
Author: Liveringhouse CL
Citation: SABCS 2018, OT2-04-05
-  Abstract 4: Regional lymph node irradiation in early stage breast cancer: An EBCTCG meta-analysis of 13,000 women in 14 trials
Author: Dodwell D
Citation: SABCS 2018, GS4-02



Day 1, Saturday 19th January 2019

-  Abstract 5: Patient-Reported Outcomes Over 5 Years After Whole- or Partial-Breast Radiotherapy: Longitudinal Analysis of the IMPORT LOW (CRUK/06/003) Phase III Randomized Controlled Trial
Author: Indrani S. Bhattacharya, et al.
Citation: J Clin Oncol. 2018 Dec 11;JCO1800982. [Epub ahead of print]
-  Abstract 6: Effects of Surgery With Salvage Stereotactic Radiosurgery Versus Surgery With Whole-Brain Radiation Therapy in Patients With One to Four Brain Metastases (JCOG0504): A Phase III, Noninferiority, Randomized Controlled Trial
Author: Takamasa Kayama, et al.
Citation: J Clin Oncol. 2018 Jun 20;JCO2018786186. [Epub ahead of print]
-  Abstract 7: Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial
Author: Rebekka Schäfer, et al.
Citation: Lancet Oncol. 2018 Jun;19(6):834-844
-  Abstract 8: Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial
Author: Galina Velikova
Citation: Lancet Oncol. 2018 Nov;19(11):1516-1529

10:30 - 11:10


 **Panel Discussion: Loco-regional**


11:10 - 11:30

 **Tea/Coffee Break**

11:30 - 13:30 SESSION 2 : HER2 POSITIVE BREAST CANCER

11:30 - 11:40


-  Abstract 1: PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results
Author: Helena Margaret Earl
Citation: ASCO 2018, Abstract 506

-  Abstract 2 : PHARE randomized trial final results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer

Author: Xavier Pivot


Citation: SABCS 2018, GS2-07

11:40 - 11:50

-  Abstract 3 : Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: primary results from KATHERINE

Author: Geyer Jr

Citation: SABCS 2018, GS1-10

-  Abstract 4 : Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

Author: Mette S van Ramshorst


Citation: Lancet Oncol. 2018 Dec;19(12):1630-1640

11:50 - 12:00

-  Abstract 5: A randomized community-based trial of an angiotensin converting enzyme inhibitor, lisinopril or a beta blocker, carvedilol for the prevention of cardiotoxicity in patients with early stage HER2-positive breast cancer receiving adjuvant trastuzumab

Author: Munster P

Citation: SABCS 2018, GS5-01


-  Abstract 6: First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial

Author: Rimawi M

Citation: J Clin Oncol. 2018 Oct 1;36(28):2826-2835

12:00 - 12:10

Rapid Review 3 : HER2 Positive Breast Cancer




-  Abstract 1 : Evaluation of trastuzumab without chemotherapy as a postoperative adjuvant therapy in HER2-positive elderly breast cancer patients: Randomized controlled trial (RESPECT)

Author: Masataka Sawaki

Citation: ASCO 2018, Abstract 510







Day 1, Saturday 19th January 2019

-  Abstract 2 : Final overall survival (OS) analysis of PHEREXA: A randomized phase III trial of trastuzumab (H) + capecitabine (X) 3 pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy
Author: Ander Urruticoechea
Citation: ASCO 2018, Abstract 1013
-  Abstract 3 : 9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio
Author: Pier franco Conte
Citation: ESMO 2018, Abstract 191PD_PR
-  Abstract 4 : Results from KATE2, a randomized phase 2 study of atezolizumab (atezo)+trastuzumab emtansine (T-DM1) vs placebo (pbo)+T-DM1 in previously treated HER2+ advanced breast cancer (BC)
Author: Emens LA
Citation: SABCS 2018, PD3-01

12:10 - 12:20

Rapid Review 4: HER2 Positive Breast Cancer

-  Abstract 1: SOLT1-1303 PATRICIA phase II trial (STAGE 1) Palbociclib and trastuzumab in postmenopausal patients with HER2-positive metastatic breast cancer
Author: Ciruelos E
Citation: SABCS 2018, PD3-03
-  Abstract 2: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT trial
Author: Smyth LM
Citation: SABCS 2018, PD3-06
-  Abstract 3: Central nervous system as first site of relapse in patients with HER2 positive early breast cancer treated in the BCIRG-006 trial
Author: Chan A
Citation: SABCS 2018, PD3-12
-  Abstract 4 : Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44)
Author: Michael Untch
Citation: J Clin Oncol. 2018 May 1;36(13):1308-1316

12:20 - 13:00

 **Panel Discussion HER2 Positive Breast Cancer**

13:00 - 13:30

Keynote 2 : HER2 positive breast cancer: Miles to Go...


Speaker: Dr. Shanu Modi

13:30 - 14:30

 **Lunch Break**


14:30 - 14:45

Rapid Review 5 : Supportive Care in Breast Cancer

 Abstract 1: Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo controlled D-CARE study


Author: Robert E. Coleman

Citation: ASCO 2018, ABSTRACT 501

 Abstract 2: Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial


Author: Michael Gnant

Citation: ASCO 2018, ABSTRACT 500

 Abstract 3: Lifestyle intervention and effect on disease-free survival in early breast cancer pts: Interim Analysis from the randomized SUCCESS C study


Author: Janni W

Citation: SABCS 2018, Abstract GS5-03

 Abstract 4: Development and validation of a chemotherapy toxicity (Chemo Tox) risk score for older patients (Pts) with breast cancer (BC) receiving adjuvant/neoadjuvant treatment (Adjuvant Tx): A R01 and BCRF funded prospective multicenter study

Author: Hurria A

Citation: SABCS 2018, Abstract GS6-04

 Abstract 5: Age and the Risk of Paclitaxel-Induced Neuropathy in Women with Early-Stage Breast Cancer (Alliance A15141): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101

Author: Barginear M

Citation: Oncologist. 2018 Nov 8. pii: theoncologist.2018-0298. [Epub ahead of print]



Day 1, Saturday 19th January 2019


-  Abstract 6: Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715)
Author: Hershman DL
Citation: J Natl Cancer Inst. 2018 Jun 1;110(6):669-676
-  Abstract 7: Risk-Imaging Mismatch in Cardiac Imaging Practices for Women Receiving Systemic Therapy for Early-Stage Breast Cancer: A Population-Based Cohort Study
Author: Paaladinesh Thavendiranathan
Citation: J Clin Oncol. 2018 May 23;JCO2018779736. [Epub ahead of print]
-  Abstract 8: Cardiovascular Toxicity in Cancer Survivors: Current Guidelines and Future Directions
Author: Carlyn Tan
Citation: <https://www.acc.org/latest-in-cardiology/articles/2018/06/29/12/57/cv-toxicity-in-cancer-survivors>
-  Abstract 9: Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review
Author: Anthony Matthews
Citation: BMJ. 2018 Oct 8;363:k3845
-  Abstract 10: Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer
Author: Naomi B. Boekel
Citation: Br J Cancer. 2018 Aug;119(4):408-418
-  Abstract 11: Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data
Author: Matteo Lambertini, et al.
Citation: J Clin Oncol. 2018 Jul 1;36(19):1981-1990
-  Abstract 12: Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers
Author: Joanne Kotsopoulos, et al.
Citation: JAMA Oncol. 2018 Aug 1;4(8):1059-1065

14:45 - 17:30 SESSION 3: ER POSITIVE BREAST CANCER

14:45 - 15:15


 **Debate: What is the most appropriate setting to use CDK 4/6 inhibitors?**

15:15 - 15:30

 **Abstract 1: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer**

Author: Joseph A. Sparano

Citation: N Engl J Med. 2018 Jul 12;379(2):111-121

 **Abstract 2: Tailoring Adjuvant Endocrine Therapy for Pre-menopausal Breast Cancer**

Author: Francis PA

Citation: N Engl J Med. 2018 Jul 12;379(2):122-137

 **Abstract 3: Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials**

Author: Poornima Saha, et al.


Citation: J Clin Oncol. 2017 Sep 20;35(27):3113-3122

15:30 - 15:40

 **Abstract 4: Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the Phase 3 SOLAR-1 trial**

Author: Fabrice André

Citation: ESMO 2018, Abstract LBA3_PR

 **Abstract 5: Phase III study of taselelisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER**

Author: Jose Baselga

Citation: ASCO 2018, Abstract LBA1006

15:40 - 15:50


Abstract 6: Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

Author: Nicholas C. Turner

Citation: N Engl J Med. 2018 Nov 15;379(20):1926-1936



Day 1, Saturday 19th January 2019

 Abstract 7: A prospective randomized multi-center open-label phase III trial of extending aromatase-inhibitor adjuvant therapy to 10 years - Results from 1697 postmenopausal women in the N-SAS BC 05 trial: Arimidex extended adjuvant randomized study (AERAS)

Author: Ohtani S

Citation: SABCS 2018, GS3-04


15:50 - 16:20



Tea/Coffee Break


16:20 - 16:35

Rapid Review 6: ER Positive Breast Cancer

 Abstract 1 : PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib


Author: Dowsett M

Citation: SABCS 2018, GS3-02

 Abstract 2: Everolimus Plus Exemestane vs Everolimusor Capecitabine Monotherapy for EstrogenReceptor-Positive, HER2-Negative Advanced Breast Cancer The BOLERO-6 Randomized Clinical Trial


Author: Guy Jerusalem, et al.

Citation: JAMA Oncol. 2018 Oct 1;4(10):1367-1374

 Abstract 3 : Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomised phase 3 trial


Author: Tripathy D

Citation: Lancet Oncol. 2018 Jul;19(7):904-915

 Abstract 4: Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3


Author: Slamon DJ

Citation: J Clin Oncol. 2018 Aug 20;36(24):2465-2472

 Abstract 5: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer


Author: G N Hortobagyi

Citation: Ann Oncol. 2018 Jul 1;29(7):1541-1547

-  Abstract 6: Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5

Author: Mitch Dowsett

Citation: J Clin Oncol. 2018 Jul 1;36(19):1941-1948


-  Abstract 7: Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Author: Sabino De Placido

Citation: Lancet Oncol. 2018 Apr;19(4):474-485


16:35 - 16:50

Rapid Review 7 : ER Positive Breast Cancer

-  Abstract 1 : nextMONARCH 1: Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in HR+, HER2- advanced breast cancer


Author: Hamilton E

Citation: SABCS 2018, PD1-11

-  Abstract 2 : Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (mBC)


Author: Aditya Bardia

Citation: ASCO 2018, Abstract 1004

-  Abstract 3 : Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer


Author: P Cottu

Citation: Ann. Oncol 2018 Oct 11. [Epub Ahead of Print]

-  Abstract 4: Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial

Author: Irene L. Wapnir, et al.

Citation: J Clin Oncol. 2018 Apr 10;36(11):1073-1079


-  Abstract 5: Male Breast Cancer: An Updated Surveillance, Epidemiology, and End Results Data Analysis

Author: Liu N, et al.

Citation: Clin Breast Cancer. 2018 Oct;18(5):e997-e1002



Day 1, Saturday 19th January 2019

 Abstract 6: Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer

Author: Azael Freites-Martinez, et al.

Citation: JAMA Dermatol. 2018 Jun 1;154(6):670-675

16:50 - 17:30

 **Panel Discussion: ER Positive Breast Cancer**

Moderator: Dr. Hope Rugo

17:30 - 17:40

Emerging Evidence- Identifying and addressing unmet needs in women with cancer

17:40 - 17:50

Indian experience with scalp cooling: Dose it really work?

19:30 Onwards

 **Dinner at ITC**



Scientific Program

Day 2, Sunday 20th January 2019


09:00 - 10:15 SESSION 4: TRANSLATIONAL SCIENCE IN BREAST CANCER

09:00 - 09:10

 Abstract 1: Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer Secondary Analysis of the NeoALTTO Randomized Clinical Trial

Author: Ryan Powles, et al.


Citation: JAMA Oncol. 2018 Nov 1;4(11):e181564. [Epub 2018 Nov 8]

 Abstract 2 : Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer. A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial

Author: Stephen J. Luen


Citation: JAMA Oncol. 2018 Oct 1;4(10):1335-1343

09:10 - 09:20

 Abstract 3 : Towards a human breast cell atlas

Author: Seth TK


Citation: SABCS 2018, GS1-02

 Abstract 4 : Landscape of the breast tumour microenvironment at single-cell resolution

Author: Swarbrick A


Citation: SABCS 2018, GS1-01.

09:20 - 09:35

 Abstract 5 : The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers


Author: Razavi P

Citation: Cancer Cell. 2018 Sep 10;34(3):427-438.e6

 Abstract 6: Accurate classification of BRCA1 variants with saturation genome editing

Author: Gregory M. Findlay

Citation: Nature. 2018 Oct;562(7726):217-222

 Abstract 7: Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing

Author: Hermela Shimelis





Citation: J Natl Cancer Inst. 2018 Aug; 110(8): 855-862



Day 2, Sunday 20th January 2019

09:35 - 09:50

Rapid Review 8: Translational Science in Breast Cancer

-  Abstract 1: Dynamics of breast cancer relapse reveal molecularly defined late recurring ER-positive subgroups: Results from the METABRIC study
Author: Curtis C, et al.
Citation: SABCS 2018, GS3-06
-  Abstract 2 : Immune parameters associated with survival in triple negative and HER2-positive breast cancer patients with 10 years of follow-up
Author: Solinas C
Citation: SABCS 2018, PD5-09
-  Abstract 3: Effect of mistimed eating patterns on breast and prostate cancer risk (MCC-Spain Study)
Author: Manolis Kogevinas, et al.
Citation: Int J Cancer. 2018 Nov 15; 143(10): 2380-2389.
-  Abstract 4 : Immune characterization of breast cancer metastasis: prognostic implications
Author: Maria Vittoria Dieci
Citation: Breast Cancer Res. 2018; 20: 62.

09:50 - 10:15

Keynote 3: Utility of CTC & ctDNA in the Management of Breast Cancer

Speaker: Dr. Shaheenah Dawood

10:15 - 10:30


Special Announcements : WCI-NAG Foundation Research Awards

10:30 - 10:45

 Tea/Coffee Break


10:45 - 12:50 SESSION 5 : TRIPLE NEGATIVE BREAST CANCER

10:45 - 10:55

 Abstract 1 : IMpassion130: Results from a global, randomised, double-blind, phase 3 study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naïve, locally advanced or metastatic triple-negative breast cancer (mTNBC)

Author: Peter Schmid


Citation: ESMO 2018, Abstract LBA1_PR

 Abstract 2 : Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer

Author: Traina TA


Citation: J Clin Oncol. 2018 Mar 20;36(9):884-890.

10:55 - 11:05

 Abstract 3 : Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

Author: S Loibl


Citation: Ann Oncol. 2018 Dec 1;29(12):2341-2347

 Abstract 4 : Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial

Author: Schneeweiss A


Citation: Eur J Cancer. 2019 Jan;106:181-192

11:05 - 11:15

 Abstract 5 : Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer

Author: Martín M

Citation: SABCS 2018, GS2-04

 Abstract 6 : Impact of the delayed initiation of adjuvant chemotherapy in the outcomes of triple negative breast cancer

Author: Morante Z

Citation: SABCS 2018, GS2-05



Day 2, Sunday 20th January 2019

11:15 - 11:25



Abstract 7 : Nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

Author: Yardley DA

Citation: Ann Oncol. 2018 Aug 1;29(8):1763-1770



Abstract 8: Carboplatin in BRCA1/2-mutated and triplenegativebreast cancer BRCAness subgroups:the TNT Trial

Author: Andrew Tutt, et al.

Citation: Nat Med. 2018 May;24(5):628-637

11:25 - 12:10

Keynote 4 : Evolving Therapeutic Strategies in Triple Negative and ER Positive Breast Cancer: Immunotherapy, PARP Inhibition & Beyond

Speaker: Dr. Hope Rugo

12:10 - 12:50



Panel Discussion: Triple Negative Breast Cancer

12:50 - 13:00



Feedback and Vote of Thanks

13:00 Onwards



Lunch and Departure

Sat 19th - Sun 20th Jan 2019 | ITC Grand Central, Parel, Mumbai

Registration Form

(Please fill the form in capital letters)

Participants Details:

Full Name: _____

Mobile No: _____ Email Id: _____

Institution: _____

Department: _____ Specialization: _____

Postal Address: _____

City: _____ State: _____

Payment Details:

Amount: _____

DD/Cheque No: _____

Bank Name: _____

Conference Registration Fee

Faculty / Delegates	Rs. 1000/-
Students	Rs. 500/-

Please visit our website www.yearinreview.in for online registration.

If you are facing any technical issues in online registration you can make cheque or demand draft in favor of "Nag Foundation" and courier it to below mentioned address of conference secretariat along with registration form.

Conference Secretariat :



Rekha Ghorpade

RIVER ROUTE Creative Group LLP

Unit No.9 , Cama Industrial Premises Co-Op Society Ltd. Sunnil Compound,

Lower Parel (W), Mumbai - 400 013

Mobile: +91 8082764779 Tel: +91 22 24931357/58, Email: yir.breastcancer@gmail.com